1. Importance of cerebrospinal fluid examination in differential diagnosis of Devic’s neuromyelitis optica by multiple sclerosis

   • R. Bergamaschi

   NEWS AND VIEWS Pages: 95 - 96

2. CT-guided stereotactic biopsies of brain stem lesions: personal experience and literature review

   • E. J. Boviatsis
   • A. T. Kouyialis
   • D. E. Sakas

   ORIGINAL Pages: 97 - 102

3. MMPI personality profiles in patients with primary chronic daily headache: a case-control study

   • M. E. Bigal
   • F. D. Sheftell
   • S. M. Baskin

   ORIGINAL Pages: 103 - 110

4. Electromagnetic waves of 900 MHz in acute pentylenetetrazole model in ontogenesis in mice

   • O. O. Erdinc
   • M. C. Baykul
   • G. Ozdemir

   ORIGINAL Pages: 111 - 116

5. Interleukin-18 in acute ischaemic stroke patients

   • J. Zaremba
   • J. Losy

   ORIGINAL Pages: 117 - 124

6. Legal and assistance aspects of Alzheimer’s disease: analysis of 100 cases

   • R. M. Ruggieri
   • F. Piccoli

   ORIGINAL Pages: 125 - 129

7. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse

   • E. Milano
   • A. Di Sapio
   • A. Bertolotto

   CASE REPORT Pages: 130 - 133

8. Association of spondylocostal dysostosis and type I split cord malformation

   • V. Etus
   • S. Ceylan
   • S. Ceylan

   CASE REPORT Pages: 134 - 137

9. Creutzfeldt-Jakob disease associated with high titer of antithyroid autoantibodies: case report and literature review

   • G. Cossu
   • M. Melis
   • A. Spissu

   CASE REPORT Pages: 138 - 140

10. A possible case of unruptured middle cerebral artery aneurysm presenting as epileptic seizures

    • E. Zambrelli
    • A. Cavallini
    • G. Micieli

    CASE REPORT Pages: 141 - 144

11. Sildenafil and transient global amnesia

    • C. Gandolfo
    • A. Sugo
    • M. Del Sette

    LETTER Pages: 145 - 146

12. ¹²³I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy

    • A. Antonini
    • R. Benti
    • P. Gerundini

    ORIGINAL Pages: 149 - 150

13. Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease

    • A. Antonini
    • G. Marotta
    • S. M. Gaini

    ORIGINAL Pages: 151 - 152

14. Cognitve estimation: comparison of two tests in nondemented parkinsonian patients

    • I. M. Appollonio
    • A. Russo
    • L. Frattola

    ORIGINAL Pages: 153 - 154

15. Proteome analysis of mesencephalic tissues: evidence for Parkinson’s disease

    • M. Basso
    • S. Giraudo
    • M. Fasano

    ORIGINAL Pages: 155 - 156

16. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson’s disease

    • F. Blandini
    • A. Mangiagalli
    • G.. Nappi

    ORIGINAL Pages: 157 - 158

17. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism

    • V. Bonifati
    • P. Rizzu
    • P. Heutink

    ORIGINAL Pages: 159 - 160

18. The diagnostic importance of the isolated supranuclear downward gaze ophthalmoplegia in progressive supranuclear palsy

    • A. Brusa
    • A. R. Bentivoglio
    • R. Stoehr

    ORIGINAL Pages: 161 - 161

19. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer’s disease

    • R. Ceravolo
    • D. Volterrani
    • U. Bonuccelli

    ORIGINAL Pages: 162 - 163

20. Presence of β-arrestin in cellular inclusions in metamphetamine-treated PC12 cells

    • A. De Blasi
    • L. Capobianco
    • A. Picascia

    ORIGINAL Pages: 164 - 165

21. Dementia, ataxia, extrapyramidal features, and epilepsy: phenotype spectrum in two Italian families with spinocerebellar ataxia type 17

    • G. De Michele
    • F. Maltecca
    • A. Bruni

    ORIGINAL Pages: 166 - 167

22. Frequency of familial aggregation in primary adult-onset cranial cervical dystonia

    • G. Defazio
    • M. S. Aniello
    • D. Martino

    ORIGINAL Pages: 168 - 169

23. Bedtime cabergoline in Parkinson’s disease patients with excessive daytime sleepiness induced by dopamine agonists

    • P. Del Dotto
    • G. Gambaccini
    • U. Bonuccelli

    ORIGINAL Pages: 170 - 171

24. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson’s disease

    • F. di Michele
    • P. Longone
    • P. Stanzione

    ORIGINAL Pages: 172 - 173

25. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease

    • A. E. Di Rosa
    • A. Epifanio
    • L. Morgante

    ORIGINAL Pages: 174 - 175

26. Natural history and clinical features of progressive supranuclear palsy: a clinical study

    • C. Diroma
    • C. Dell’Aquila
    • G. Iliceto

    ORIGINAL Pages: 176 - 177

27. Excessive daytime somnolence in Parkinson’s disease. Follow-up after 1 year of treatment

    • G. Fabbrini
    • P. Barbanti
    • G. Meco

    ORIGINAL Pages: 178 - 179

28. Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum

    • R. Fancellu
    • M.-T. Armentero
    • F. Blandini

    ORIGINAL Pages: 180 - 181

29. Amphetamines induce ubiquitin-positive inclusions within striatal cells

    • F. Fornai
    • G. Lazzeri
    • A. Paparelli

    ORIGINAL Pages: 182 - 183

30. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy

    • P. Marini
    • S. Ramat
    • M. Paganini

    ORIGINAL Pages: 184 - 185

31. Progressive supranuclear palsy: analysis of six cases

    • M. Marra
    • V. Toni
    • G. Coppola

    ORIGINAL Pages: 186 - 187

32. Neuroacanthocytosis: clinical, radiological, and neurophysiological findings in an Italian family

    • A. M. Marson
    • E. Bucciantini
    • C. Geda

    ORIGINAL Pages: 188 - 189

33. Psychometric properties of the Unified Parkinson’s Disease Rating Scale and of the Short Parkinson’s Evaluation Scale

    • E. Martignoni
    • F. Franchignoni
    • D. Picco

    ORIGINAL Pages: 190 - 191

34. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?

    • P. Martinelli
    • M. Contin
    • A. Baruzzi

    ORIGINAL Pages: 192 - 193

35. Six years’ experience in deep brain stimulation in Parkinson’s disease: advantages and limitations of use of neurophysiological intraoperative microreading

    • G. P. Nordera
    • T. Mesiano
    • V. Toso

    ORIGINAL Pages: 194 - 194

36. Sleep attacks in Parkinson’s disease: a clinical and polysomnographic study

    • C. Pacchetti
    • E. Martignoni
    • R. Manni

    ORIGINAL Pages: 195 - 196

37. The use of entacapone in patients with advanced Parkinson’s disease: 2 years’ experience

    • C. Paci
    • S. Sanguigni
    • L. Curatola

    ORIGINAL Pages: 197 - 198

38. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

    • L. Parnetti
    • A. Lanari
    • V. Gallai

    ORIGINAL Pages: 199 - 200

39. A paradoxical acute effect of levodopa in de novo parkinsonian patients: worsening of some bradykinetic components

    • C. Pasetti
    • M. M. Lualdi
    • P. Pinelli

    ORIGINAL Pages: 201 - 202

40. Caregiving and Parkinson’s disease

    • C. Pasetti
    • S. Rossi Ferrario
    • J. Galli

    ORIGINAL Pages: 203 - 204

41. Hedonistic homeostatic dysregulation in Parkinson’s disease: a short screening questionnaire

    • F. R. Pezzella
    • S. Di Rezze
    • G. Meco

    ORIGINAL Pages: 205 - 206

42. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment

    • L. Priano
    • G. Albani
    • A. Mauro

    ORIGINAL Pages: 207 - 208

43. Health-Related Quality of Life and sleep disorders in Parkinson’s disease

    • T. Scaravilli
    • E. Gasparoli
    • F. Bracco

    ORIGINAL Pages: 209 - 210

44. Progressive dysarthria: definition and clinical follow-up

    • P. Soliveri
    • S. Piacentini
    • F. Girotti

    ORIGINAL Pages: 211 - 212

45. Distal-proximal differences in limb apraxia in corticobasal degeneration but not progressive supranuclear palsy

    • P. Soliveri
    • S. Piacentini
    • F. Girotti

    ORIGINAL Pages: 213 - 214

46. Italian Huntington disease patients-data and tissue bank

    • F. Squitieri
    • M. Cannella
    • F. Pierelli

    ORIGINAL Pages: 215 - 216

47. Optimizing levodopa pharmacokinetics in Parkinson’s disease: the role of COMT inhibitor

    • F. Stocchi
    • L. Vacca
    • S. Ruggieri

    ORIGINAL Pages: 217 - 218

48. Acute akinesia or akinetic crisis in Parkinson’s disease

    • A. Thomas
    • D. Iacono
    • M. Onofrj

    ORIGINAL Pages: 219 - 220

49. Use of antiparkinsonian drugs in the Umbria Region

    • N. Vanacore
    • C. Bianchi
    • M. Rossi

    ORIGINAL Pages: 221 - 222

50. Association of tau gene polymorphism with Parkinson’s disease

    • M. Zappia
    • G. Annesi
    • A. Quattrone

    ORIGINAL Pages: 223 - 224